Coenzyme Q₀ From *Antrodia cinnamomea* Exhibits Drug-Resistant Bacteria Eradication and Keratinocyte Inflammation Mitigation to Ameliorate Infected Atopic Dermatitis in Mouse

Wei-Ling Chou¹, Tzong-Huei Lee², Tse-Hung Huang¹,³,⁴,⁵, Pei-Wen Wang⁶, Ya-Ping Chen⁷, Chin-Chang Chen¹, Zi-Yu Chang¹,⁸, Jia-You Fang⁷,⁹,¹⁰,¹¹ and Shih-Chun Yang¹²*

¹ Department of Traditional Chinese Medicine, Chang Gung Memorial Hospital, Keelung, Taiwan, ² Institute of Fisheries Science, National Taiwan University, Taipei, Taiwan, ³ School of Traditional Chinese Medicine, Chang Gung University, Taoyuan, Taiwan, ⁴ Graduate Institute of Health Industry Technology, Chang Gung University of Science and Technology, Taoyuan, Taiwan, ⁵ School of Nursing, National Taipei University of Nursing and Health Sciences, Taipei, Taiwan, ⁶ Department of Medical Research, China Medical University Hospital, China Medical University, Taichung, Taiwan, ⁷ Pharmaceutics Laboratory, Graduate Institute of Natural Products, Chang Gung University, Taoyuan, Taiwan, ⁸ School of Medicine, Institute of Traditional Medicine, National Yang-Ming University, Taipei, Taiwan, ⁹ Chinese Herbal Medicine Research Team, Healthy Aging Research Center, Chang Gung University, Taoyuan, Taiwan, ¹⁰ Research Center for Food and Cosmetic Safety and Research Center for Chinese Herbal Medicine, Chang Gung University of Science and Technology, Taoyuan, Taiwan, ¹¹ Department of Anesthesiology, Chang Gung Memorial Hospital, Taoyuan, Taiwan, ¹² Department of Cosmetic Science, Providence University, Taichung, Taiwan

Atopic dermatitis (AD) is an inflammatory skin disease that is usually accompanied by *Staphylococcus aureus* infection due to cutaneous barrier-function damage. Benzenoid compounds from *Antrodia cinnamomea* are known to exhibit antibacterial and anti-inflammatory activities. This study sought to investigate the potential of benzenoids for treating bacteria-infected AD. The compounds were screened against methicillin-resistant *S. aureus* (MRSA). Coenzyme Q₀ (CoQ₀), a key ingredient in *A. cinnamomea*, showed the strongest MRSA growth inhibition. We further tested the inhibitory effect of CoQ₀ on planktonic and biofilm MRSA. The work was also performed to explore the potential effectiveness of CoQ₀ on AD using activated keratinocytes and *in vivo* experimental AD mice as the models. The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of CoQ₀ against MRSA were 7.81 μg/ml. CoQ₀ was found to eradicate biofilm MRSA efficiently and reduce the biofilm thickness. CoQ₀ killed MRSA by inhibiting DNA polymerase and topoisomerases. A proteomic assay showed that CoQ₀ also reduced the ribosomal proteins. In the anti-inflammation study, CoQ₀ was found to erode biofilm MRSA efficiently and reduce the biofilm thickness. CoQ₀ killed MRSA by inhibiting DNA polymerase and topoisomerases. A proteomic assay showed that CoQ₀ also reduced the ribosomal proteins. In the anti-inflammation study, CoQ₀ was found to downregulate the expression of interleukin (IL)-6, chemokine (C-C motif) ligand (CCL)5, and CCL17 in HaCaT cells. CoQ₀ at 0.5 μg/ml could recover the filaggrin decreased by HaCaT activation to the normal control. We established a bacteria-infected AD-like model in mice using ovalbumin (OVA) and topically applied MRSA. Topical CoQ₀ delivery lessened the MRSA presence in the AD-like lesions by >90%. The erythema,
INTRODUCTION

Atopic dermatitis (AD) is a commonly diagnosed skin condition characterized by a heterogeneous pathogenesis such as chronic inflammation, barrier dysfunction, and pruritus (Roesner et al., 2016). AD generally begins in early childhood and affects 10% to 25% of children and 2% to 10% of adults (Nyggaard et al., 2017). The barrier deficiency caused by AD has been linked to increased bacterial infection in the skin (Sohn, 2018). More than 90% of AD patients are colonized with Staphylococcus aureus (Ong, 2014). The emergence of methicillin-resistant S. aureus (MRSA) has led to an increase in AD exacerbation due to its resistance to current antibiotics (Shi et al., 2018). The increasing resistance of bacteria in AD and the deteriorated inflammation advocate the demand for novel anti-MRSA and anti-inflammatory agents for AD treatment.

Some investigations have acknowledged that natural products are rich sources of antibacterial and anti-inflammatory potencies. Antrodia cinnamomea is a fungus inhabiting the inner cavity of Cinnamomum kanehirae Hayata. It is a traditional medicine for treating hypertension, cirrhosis, hepatitis, diarrhea, and itchy skin (Geethangili and Tseng, 2011). The main active ingredients in A. cinnamomea include terpenoids, lignans, polysaccharides, and benzenoids. The extracts and compounds of A. cinnamomea demonstrate the capability to inhibit skin inflammation (Amin et al., 2015; Tsai et al., 2015; Kuo et al., 2016). The constituents from A. cinnamomea are reported to show antimicrobial activity against both Gram-positive and Gram-negative species (Geethangili et al., 2010; Chiang et al., 2013; Lien et al., 2014). We previously isolated a series of benzenoids from A. cinnamomea and found the anti-inflammatory activity in stimulated macrophages via inducible nitric oxide synthase (iNOS) inhibition (Yang et al., 2009; Yu et al., 2016). Some scientists have also shown the usefulness of benzenoids from A. cinnamomea in suppressing inflammatory response (Chen et al., 2007; Buccini et al., 2014; Yen et al., 2018). Since AD is associated with inflammation, barrier deficiency, and bacterial infection, combined therapy with anti-inflammatory and antibacterial agents can be beneficial to alleviating the symptoms. Since A. cinnamomea effectively inhibits inflammation and bacterial growth, it is an ideal candidate for the development of anti-AD agents. We aimed to isolate benzenoid derivatives from A. cinnamomea to evaluate the capability to ameliorate AD through the reduction of inflammation and the MRSA burden. Our results exhibited that among all benzenoids tested, 2,3-dimethoxy-5-methyl-1,4-benzoquinone (coenzyme Q10, CoQ10) was the most effective antibacterial compound. Using human keratinocytes as the cell model, we demonstrated that CoQ10 could reduce the up-regulation of cytokines and chemokines. CoQ10 could also enhance the decrease in TJ-related proteins caused by keratinocyte stimulation. Here, we showed that topical CoQ10 administration remarkably improved AD symptoms and the associated MRSA burden in the mouse model.

Keywords: Antrodia cinnamomea, coenzyme Q10, atopic dermatitis, methicillin-resistant S. aureus, skin delivery

MATERIALS AND METHODS

Compounds

The agar-cultured mycelium of A. cinnamomea was used to prepare the extract in 95% ethanol for 3 days at room temperature. The mycelium of A. cinnamomea in an agar plate is shown in Supplementary Figure 1. A voucher specimen of A. cinnamomea has been deposited at the herbarium of the Institute of Fisheries Science, National Taiwan University. The fermentation of A. cinnamomea and the extraction and isolation of benzenoids were the same as in the previous study (Yang et al., 2009). All compounds were identified by nuclear magnetic resonance (NMR) and mass spectrometry. As shown in Figure 1A, the following six benzenoid analogs were obtained and identified: 2,4-dimethoxy-6-methylbenzene-1,3-diol (compound 1), 6-methyl-2,3,4-trimethoxyphenol (compound 2), CoQ10 (compound 3), 2-methoxy-6-methylbenzene-1,4-diol (compound 4), 2,3-(methylenedioxy)-6-methylbenzene-1,4-diol (compound 5), and 1,4-dimethoxy-2,3-methylenedioxy-5-methylbenzene (compound 6). The spectra of 1H NMR for all compounds are shown in Supplementary Figure 2. The purity of all compounds was over 98%. The profiles of spectrometry of each compound are listed below.

Compound 1: colorless crystals; UV (MeOH) λmax (log ε) 285 (3.39) nm; IR (ZnSe) νmax 3438, 2941, 1503, 1477, 1379, 1320, 1198, 1123, 1072, 898 cm⁻¹; 1H NMR (CDCl3, 300 MHz): δ2.15 (3H, s), 3.75 (3H, s), 3.80 (3H, s), 6.44 (1H, s); electron ionization mass spectra (EIMS) m/z 184 [M]+, 105 (100), 77 (85), 71 (70).

Compound 2: amorphous powder; UV (MeOH) λmax (log ε) 287 (3.57) nm; IR (ZnSe) νmax 3440, 2935, 2843, 1496, 1423, 1362, 1203, 1124, 1082 cm⁻¹; 1H NMR (CDCl3, 300 MHz): δ2.15 (3H, s), 3.76 (3H, s), 3.80 (3H, s), 3.83 (3H, s), 6.50 (1H, s); EIMS m/z: 198 [M]+, 183 (25), 105 (44), 77 (64).

Compound 3: needles; UV (MeOH) λmax (log ε) 265 (3.72) nm; IR (ZnSe) νmax 2927, 2858, 1657, 1604, 1455, 1275, 1207, 1142, 1074, 887 cm⁻¹; 1H NMR (CDCl3, 300 MHz): δ2.01 (3H, d, J = 1.5 Hz), 3.97 (3H, s), 4.00 (3H, s), 6.42 (1H, q, J = 1.5 Hz); ESIMS m/z: 205 [M + Na]+.

Compound 4: colorless crystals; UV (MeOH) λmax (log ε) 266 (3.82) nm; IR (ZnSe) νmax 3423, 1648, 1604, 1495, 1445, 1366, 1318, 1230, 1148, 1080 cm⁻¹; 1H NMR (CDCl3, 300 MHz): δ2.18 (3H, s), 3.81 (3H, s), 6.19 (1H, d, J = 2.7 Hz), 6.28 (1H, d, J = 2.7 Hz); EIMS m/z: 154 [M]+, 98 (89), 71 (100).

...
Compound 5: colorless crystals; UV (MeOH) $\lambda_{max}$ (log $\varepsilon$) 283 (3.26) nm; IR (ZnSe) $\nu_{max}$ 3250, 1641, 1475, 1398, 1365, 1283, 1214, 1124, 1049, 1017 cm$^{-1}$; $^1$H NMR (CD$_3$OD, 300 MHz): $\delta_H$ 2.08 (3H, d, $J = 0.7$ Hz), 5.84 (2H, s), 6.16 (1H, q, $J = 0.7$ Hz); ESIMS $m/z$: 191 [M + Na]$^+$. 

Compound 6: colorless crystals; $^1$H NMR (CDCl$_3$, 300 MHz): $\delta_H$ 2.16 (3H, s), 3.83 (3H, s), 3.86 (3H, s), 5.91 (2H, s), 6.28 (1H, s).

The Strains of S. aureus

S. aureus (ATCC6538) and MRSA (ATCC33591) were purchased from American Type Culture Collection. The clinical isolates of MRSA (KM-1) and vancomycin-intermediate S. aureus (VISA, KV-2) were the gifts of Kaohsiung Medical University Hospital. All S. aureus species were grown in tryptic soy broth (TSB) at 37°C and 150 rpm.

Agar Diffusion Assay

The agar diffusion assay was carried out by inoculating the microbes at OD$_{600}$ = 0.7 in 0.75% tryptone soya broth (TSB) agar. The mixture of microbes and agar (5 ml) was dispersed into a dish for 15 min. The compounds (1 mg/ml, 10 $\mu$l) were dropped onto the agar. The compounds were chemically stable under the conditions used. The diameter of the clear zone without bacteria was measured after a 16-h incubation.

Minimum Inhibitory Concentration and Minimum Bactericidal Concentration

Minimum inhibitory concentration (MIC) was measured using a broth 2-fold serial dilution technique. The microbes were diluted by TSB to obtain a concentration of OD$_{600}$ = 0.01 (2 x 10$^6$ colony-forming unit (CFU)/ml). The bacteria were exposed to several dilutions of the compounds with TSB and incubated at 37°C for 20 h. The absorbance of the mixture was detected by an enzyme-linked immunosorbent assay (ELISA) reader at 595 nm. A reading of <0.1 was recognized as MIC. The microbe suspension was diluted by phosphate-buffered saline (PBS) and plated on a TSB plate. The plate was incubated at 37°C for 20 h. The CFU was then counted. Minimum bactericidal concentration (MBC) was defined as the lowest compound concentration to kill $\geq$99.9% of the stains.
Growth Curve of CoQ₉-Treated MRSA
A broth dilution method was used to detect a MRSA growth curve within 48 h. CoQ₉ at the concentration of 1.85 to 62.5 μg/ml was pipetted into TSB (200 μl) with MRSA (2 × 10⁵ CFU/ml). The real-time measurement of OD₅₉₅ was monitored using a multimode plate reader (BioTek).

MRSA Survival Detected by Flow Cytometry and Fluorescence Microscopy
MRSA was diluted by TSB to obtain an OD₆₀₀ of 0.1. The bacteria pellet was achieved by centrifugation at 12,000 rpm for 3 min, and then suspended in culture medium with CoQ₉ (19–312 μg/ml). The samples were stained using a Live/Dead BacLight™ kit after a 2-h incubation at 37°C and 150 rpm. The samples were assayed by flow cytometry (BD Biosciences) to determine MRSA viability. Fluorescence microscopy was also applied to visualize the live and dead MRSA.

Assessing MRSA Biofilm
The construction of MRSA biofilm was described previously (Alalaiwe et al., 2018). After the CoQ₉ (78–312 μg/ml) or cetylpyridinium chloride (CPC, 75 μg/ml) treatment for 24 h, the biofilm was rinsed using PBS to remove the loosely adherent planktonic MRSA and was then suspended in PBS. The recovered MRSA outside the biofilm and the MRSA inside the biofilm were placed in an agar plate for 24 h to count CFU. The CoQ₉- or CPC-treated biofilm was stained using Live/Dead BacLight™. The 3D structure, thickness, and fluorescence of the biofilm were observed by confocal microscopy (Leica).

Cytotoxicity of CoQ₉-Treated Keratinocytes
HaCaT cell line (ATCC number: PCS-200-011) was cultured in DMEM supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin in 5% CO₂ at 37°C. After CoQ₉ incubation at 0.25 to 16 μg/ml for 24 h, (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution at 5 mg/ml was added to the plate for 4 h. The formazan precipitate was solubilized with DMSO and then read by an ELISA reader at 550 nm to determine keratinocyte viability.

Activating Keratinocytes by Tumor Necrosis Factor-α and Interferon-γ
HaCaT were stimulated by tumor necrosis factor (TNF)-α and interferon (IFN)-γ (20 ng/ml) to activate the inflammatory condition. CoQ₉ at 0.25 to 2 μg/ml was added to the cells simultaneously. After a 24-h incubation, the culture supernatant was harvested for cytokine and chemokine analysis. The cells were pipetted into the lysis buffer to gain the tight junction (TJ)-related proteins from the whole cell lysate for a Western blotting assay.

ELISA Assay
The cytokines and chemokines released from keratinocytes were detected by the ELISA method. The levels of interleukin (IL)-6, chemokine (C-C motif) ligand (CCL)5, and CCL17 were measured using commercial kits (ELISA MAX Deluxe Set, BioLegend) based on the manufacturer's instructions. The detailed procedures for the ELISA assay were described in our previous study (Lin et al., 2018).
Immunoblotting Assay  
The separated proteins were transferred to the nitrocellulose membrane and probed with primary antibodies against filaggrin, involucrin, integrin β1, and gliceraldehyde-3-phosphate dehydrogenase (GAPDH) overnight at 4 °C. The membrane was incubated with anti-rabbit monoclonal antibody for 1 h. The bound antibody was observed using enhanced chemiluminescence reagent. The protein amount was quantified by the ratio of the densitometric measurement of the proteins to the corresponding GAPDH.

Animals  
Eight-week-old male Balb/c mice were purchased from the National Laboratory Animal Center (Taipei, Taiwan). One-week-old male or female pigs were provided by Pigmodel Animal Technology (Miaoli, Taiwan). They were housed at an ambient temperature of 25 ± 2 °C and a relative humidity of 50 ± 10% on a 12-h light/dark cycle. All animals were treated in strict accordance with the recommendations set forth in the guidelines of the Institutional Animal Care and Use Committee of Chang Gung University (CGU15-083). Food and water were given ad libitum. All efforts were made to attenuate suffering.

Skin Absorption of CoQ₀  
The in vitro Franz cell approach was used to determine cutaneous CoQ₀ delivery into the skin. The excised pig skin was mounted between the donor and receptor with the stratum corneum (SC) facing the donor side. The donor was filled with 0.5 ml of CoQ₀ (1 mg/ml) in 30% ethanol/pH 7.4 buffer. The receptor medium was the same as the vehicle in the donor. The penetration area available was 0.79 cm². The receptor temperature was maintained at 37 °C with a stirring rate of 600 rpm triggered by a stir bar. A 300-μl aliquot in the receptor was withdrawn at the determined intervals. At 24 h post-treatment, the skin was removed to evaluate the skin deposition of the compound. The skin was extracted by methanol in a MagNA Lyser homogenizer (Roche); then the homogenate was centrifuged at 10,000g for 10 min. All samples were analyzed to obtain the absorption level by high-performance liquid chromatography (HPLC). The stationary phase of HPLC was a 25-cm-long, 4-mm inner diameter reverse phase C18 column (Merck). The mobile phase consisted of methanol and double-distilled water (50:50) at a flow rate of 1 ml/min. The wavelength of the UV/visible detector was 240 nm.

Establishing a Mouse Model With Combined AD-Like Lesions and MRSA Infection  
This method was adapted from the previous study that created an animal model to simulate MRSA-infected AD-like skin (Yang et al., 2018). Briefly, the mouse was treated with an intraperitoneal injection of ovalbumin (OVA, 5.3 μg/kg) for 13 d and then topical OVA administration (5.3 μg/kg) for 3 d. MRSA with a volume of 100-μl (OD₆₀₀ = 1) was dropped on a gauze for topical application on the dorsal skin on day 15. On days 16 and 17, 1 mg/ml CoQ₀ with a volume of 100 μl in 15% ethanol/PBS was applied to the lesional skin. The dose of 1 mg/ml was selected for CoQ₀ which was the same as the skin absorption test. CoQ₀ showed facile penetration in this applied concentration. The mice were divided into different groups with 6 animals per group. The gross observation of the skin surface with or without CoQ₀ intervention was accomplished using a handheld digital magnifier (M&T Optics). The level of transepidermal water loss (TEWL) was monitored by Tewameter (Courage and Khazaka). The lesional skin was excised to measure MRSA CFU and cytokines. The skin samples were sliced to a thickness of 5 μm for hematoxylin and eosin (H&E) and immunohistochemical (IHC) staining. The skin slices of formalin-fixed, paraffin-embedded sections were prepared for IHC. The sections were incubated with anti-lymphocyte antigen 6 complex locus G6D (Ly6G) or anti-filaggrin antibody for 1 h at room temperature, washed with saline containing 0.5% Tween 20, and then incubated at ambient temperature with biotinylated donkey anti-goat immunoglobulin G (IgG) for 20 min. Color reaction was observed by using the Vectastain Elite avidin-biotin complex kit (Vector Laboratories). All photomicrographs of histopathology were taken by Leica DMi8 microscopy.

Skin Tolerance of CoQ₀  
The safety of topically applied CoQ₀ was assessed in the skin of healthy mice. CoQ₀ (1 mg/ml) in 15% ethanol/PBS was applied daily (600 μl) on the dorsal skin for 4 days. The TEWL and skin pH were monitored every day. The erythema quantified by colorimetry (Yokogawa) was also detected. The skin was excised for H&E staining after a 4-day treatment.

Statistical Analysis  
The statistical difference in the data of the different treatments with or without CoQ₀ was analyzed using the Kruskal-Wallis test. The post hoc test for checking individual differences was Dunn’s test. The 0.05, 0.01, and 0.001 levels of probability were taken as statistically significant.

RESULTS  
CoQ₀ Shows the Strongest Activity Against MRSA Among the Benzenoids  
We began the antibacterial investigation by administering the benzenoids (1 mg/ml) to MRSA in agar to calculate the inhibition zone. The results illustrated in Figure 1B demonstrate that CoQ₀ showed the greatest MRSA inhibition, followed by compounds 4, 5, and 1. Compounds 2 and 6 had no effect on forming the clear inhibition zone. The results summarized in Table 1 support the findings described previously. The lowest MIC and MBC (7.81 μg/ml) were exhibited in the CoQ₀ group, followed by compounds 4 and 5. CoQ₀ elicited a concentration-dependent inhibition of MRSA, S. aureus, and clinical isolates of MRSA (KM-1) and VISA (KV-2) as shown in Figure 1C. The antimicrobial activity of CoQ₀ against different microorganisms was also investigated using MIC and MBC. As shown in Table 2, a high antibacterial potency for CoQ₀ was observed with MIC between 7.81 and 31.25 μg/ml.

The growth curves realized on MRSA treated with CoQ₀ have proved the results of the inhibition zone and MIC/MBC (Figure 1D). CoQ₀ suppressed MRSA viability at all concentrations tested.
Ameliorating Atopic Dermatitis and the MRSA Infection

Chou et al.

CoQ₀-treated MRSA were further stained using a Live/Dead kit to discover the survival rate by flow cytometry. The representative diagram of the live/dead strain in Figure 1E demonstrates a negligible MRSA killing at CoQ₀ concentrations of ≤78 μg/ml. The survival rate of 156 and 312 μg/ml was 63% and 0%, respectively. Visual confirmation of the effect of CoQ₀ on MRSA eradication was obtained using fluorescence microscopy. In Figure 1F, the green signal stained by SYTO9 represents live MRSA, whereas the red fluorescence stained by propidium iodide (PI) indicates bacterial membrane disruption resulting in a diffuse distribution in the cytoplasm. The green dots decreased following the increase of the CoQ₀ concentration. However, the red dots were limited, although the concentration was significantly increased.

CoQ₀ Inhibits Biofilm Formation

A biofilm increases the virulence of pathogens and their resistance to antibiotics. Figure 2A demonstrates the corresponding number of MRSA inside the biofilm. CoQ₀ (1.85–62.5 μg/ml) in a dose-dependent manner.

| Compound | MIC (μg/ml) | MBC (μg/ml) |
|----------|-------------|-------------|
| 1        | 125         | 125         |
| 2        | 250         | 500         |
| 3 (CoQ₀) | 7.81        | 7.81        |
| 4        | 15.63       | 31.25       |
| 5        | 31.25       | 62.5        |
| 6        | 500         | 500         |

| Compound | MIC (μg/ml) | MBC (μg/ml) |
|----------|-------------|-------------|
| MRSA     | 7.81        | 7.81        |
| S. aureus| 15.63–31.25 | 15.63–31.25 |
| KM-1     | 31.25       | 31.25       |
| KV-2     | 15.63–31.25 | 31.25       |

CoQ₀ inhibits biofilm formation by decreasing the number of MRSA inside the biofilm. Figure 2B demonstrates the corresponding number of MRSA outside the biofilm. CoQ₀ significantly decreases the biofilm thickness as shown in Figure 2C. Figure 2D shows the quantification of green fluorescence intensity (live bacteria) of MRSA biofilm. Figure 2E shows the quantification of red fluorescence intensity (dead bacteria) of MRSA biofilm. Each value represents the mean ± SEM (n = 4). ***p < 0.001; **p < 0.01; *p < 0.05.
concentration-dependently reduced the MRSA number in the biofilm. The concentration at 312 μg/ml diminished CFU by about 4 logs, leading to killing 99.99% of the MRSA population. The comparator agent CPC exhibited a reduced CFU comparable to CoQ0 at 312 μg/ml. The 312-μg/ml CoQ0 completely eradicated MRSA outside the biofilm (Figure 2B). This effect was greater than CPC used as the positive control. The x-y-z axis image of the biofilm showed an intact structure with condensed live MRSA inside (Figure 2C). The live MRSA markedly decreased when the biofilm was incubated in the presence of CoQ0. The CoQ0-treated biofilm became less uniform and looser and thinner than the intact biofilm. CoQ0 and CPC suppressed the biofilm’s thickness to 45% and 48% of the control, respectively (Figure 2D). The quantification of green intensity in the biofilm showed a significant reduction by CoQ0 and CPC (Figure 2E). CPC incubation increased the red color by about 6-fold (Figure 2F). However, the increase in red color was limited for CoQ0. This indicates that the bacterial-membrane disruption for the cytoplasm material leakage or exogenous material entrance was not the predominant mechanism for CoQ0.

CoQ0 as the Inhibitor of DNA Polymerase and Topoisomerases for MRSA Eradication

The morphology of MRSA examined by SEM showed a minimal change after CoQ0 treatment (Figure 3A). Disruption of the bacterial membrane was observed by CPC, with the presence of a rough surface, irregular shape, and some cavities. As shown in the TEM image in Figure 3B, a large amount of cytosol was released from the porous membrane by CPC. The use of CoQ0 resulted in the MRSA membrane remaining intact. The total protein, total RNA, and genomic DNA of MRSA were analyzed as illustrated in Figures 3C–E, respectively. CoQ0 caused a significant decrease in the total amount of protein, RNA, and DNA compared to the untreated control. DNA polymerase is a major enzyme for DNA replication in MRSA. CoQ0 was evaluated for targeting enzyme inhibition using the anti-Taq PCR method to observe DNA polymerase inhibition. As shown in Figure 3F, the PCR products were lessened by CoQ0 in a concentration-dependent manner. The relaxing activity of topoisomerase I on MRSA was tested as shown in Figure 3G. CoQ0 displayed a capacity to deactivate topoisomerase I (gyrase). This result was also detectable in topoisomerase II (gyrase). Figure 3H provides the evidence that CoQ0 retarded the supercoiling activity of DNA gyrase.

The qualitative and quantitative analysis of the proteomics was conducted by mass as summarized in Table 3. The top ten proteins with the highest or lowest concentration ratios to the control were selected to be shown in this table. The most upregulated protein by CoQ0 treatment was alkyl hydroperoxide reductase. Some ATP-related proteins such as ATP-dependent zinc metalloprotease, GrpE, nucleoside diphosphate kinase, and Clpb were upregulated by CoQ0. On the other hand, the ribosomal proteins including L13, S6, S4, L21, S18, and L31 were downregulated after CoQ0 treatment.

CoQ0 Is Effective in Inhibiting Inflammation and Recovering TJ Deficiency in an HaCaT Model

As shown in Figure 4A, CoQ0 at the concentrations of ≤2 μg/ml did not exhibit considerable toxicity toward HaCaT. This compound decreased cell viability in a concentration-dependent fashion with significance at 4, 8, and 16 μg/ml. A noncytotoxic concentration of CoQ0 (0.25–2 μg/ml) was taken for further studies. Cytokines and chemokines were evaluated as biomarkers of inflammatory HaCaT. As presented in Figure 4B, combined TNF-α and IFN-γ greatly increased the level of IL-6 secreted by HaCaT compared to the level in the untreated control. The inhibition of IL-6 production was detected only at 2 μg/ml for CoQ0. The stimulators activated chemokines, including CCL5 and CCL17 (Figures 4C, D). CoQ0 dose-dependently suppressed the CCL5 and CCL17 protein levels.

Skin-barrier dysfunction and its deficiency are key features of AD. We examined the influence of CoQ0 on TJ-related proteins in the activated keratinocytes. Since TNF-α and IFN-γ as the stimulators showed a limited capacity to impair filaggrin, involucrin, and integrin β1 in HaCaT, the particulate matter (PM) pollutant standard (1649b) was utilized to achieve this aim according to the previous study (Lee et al., 2016). As illustrated in the left panel of Figure 4E, 1649b reduced filaggrin following the increase in incubation time. As shown in the right panel of Figure 4E, CoQ0 at 0.5 μg/ml was sufficient to recover filaggrin in 1649b-stimulated HaCaT to the normal baseline. The level of involucrin decreased after 1649b treatment, and CoQ0 could not promote involucrin production in the activated HaCaT (Figure 4F). CoQ0 improved the decreased protein level of integrin β1 by 1649b (Figure 4G).

CoQ0 Facilely Penetrates Into the Skin

The capability of topically applied CoQ0 to penetrate into the skin was carried out in vitro in Franz cell. As presented in Figure 5A, pig skin showed the minimal CoQ0 deposition because of its thicker and more rigid structure than rodent skin. The skin deposition indicated the uptake within the skin. CoQ0 uptake in healthy and AD-like mouse skin was 0.20 and 1.11 nmol/mg, respectively. This revealed a weak barrier of AD-like skin as proved by TJ deficiency. The tendency of CoQ0 penetration across the skin for three skin barriers was the same as that of the absorption into the skin reservoir (Figure 5B).

CoQ0 Ameliorates MRSA-Infected AD-Like Lesions In Vivo

The AD-like lesions in the mouse model were developed by both intraperitoneal and topical OVA. MRSA were topically applied on the skin for cutaneous infection. Figures 5C, D show the gross and microscopic appearance of en face mouse skin, respectively. MRSA infection led to the observation of the open wound and scaling. These symptoms were partly attenuated in the mice dosed with CoQ0. The OVA challenge displayed atopic skin symptoms, including redness, excoriation, hemorrhage, and lichenification. The MRSA-infected OVA-treated skin showed the combined appearance of infection and...
AD-like lesions. CoQ0 exhibited some lesion suppression in the MRSA-infected AD-like skin. TEWL, as an indicator of the skin-barrier nature, showed a 4-fold increase in MRSA-infected skin compared to the untreated control (Figure 5E). As seen, CoQ0 recovered the TEWL of the infected skin from 22.4 to 8.7 g/h/m². OVA treatment further weakened the barrier function of the infected skin. Topical CoQ0 administration markedly suppressed TEWL to 63% of the OVA/MRSA group. Figure 5F depicts the MRSA count in the mouse skin with different treatments. Bacterial infection increased the MRSA burden in the skin from 0 to 5.98 × 10⁵ CFU/ml. CoQ0 did not reduce the MRSA load in the infected skin. Because of the impaired barrier of the OVA-treated skin, a greater MRSA amount was found in the AD-like lesions than in the intact skin. CoQ0 reduced the pathogen burden in the OVA/MRSA group relative to the vehicle control.
| No. | Accession   | Protein                                     | MW [kDa] | Coverage | Matched peptides | Ratios to control | Biological function                                                                                                                                 |
|-----|-------------|---------------------------------------------|----------|----------|------------------|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|
| 1.  | A0A0E0VTX0  | Alkyl hydroperoxide reductase AhpD         | 19.9     | 12.35    | 2                | 2.558             | Antioxidant protein with alkyl hydroperoxidase activity. Required for the reduction of the AhpC active site cysteine residues and for the regeneration of the AhpC enzyme activity. |
| 2.  | A0A0E0VLTN4 | ATP-dependent zinc metalloprotease PshH     | 77.8     | 3.01     | 2                | 2.541             | Acts as a processive, ATP-dependent zinc metalloprotease for both cytoplasmic and membrane proteins. Plays a role in the quality control of integral membrane proteins. |
| 3.  | A0A0E0VQR7  | Delta-lysin                                 | 5.1      | 24.44    | 12               | 2.177             | Hemolysis by symbiont of host erythrocytes.                                                                                                           |
| 4.  | A0A0E0VPI1  | Protein GrpE                                | 24.0     | 31.73    | 7                | 1.749             | GrpE releases ADP from DnaK; ATP binding to DnaK triggers the release of the substrate protein, thus completing the reaction cycle. Several rounds of ATP-dependent interactions between DnaJ, DnaK and GrpE are required for fully efficient folding. |
| 5.  | A0A0E0VNU7  | Glutamate dehydrogenase                     | 47.3     | 24.53    | 12               | 1.742             | Nucleotide binding oxidoreductase activity, acting on the CH-NH2 group of donors, NAD or NADP as acceptor. Major role in the synthesis of nucleoside triphosphates other than ATP. The ATP gamma phosphate is transferred to the NDP beta phosphate via a ping-pong mechanism, using a phosphorylated active-site intermediate. Required for dimerization of active 70S ribosomes into 100S ribosomes; when added to monomeric 70S ribosomes stimulates formation of 100S dimeric ribosomes. Unlike E.coli, 100S ribosomes are present during exponential growth, peak during early stationary phase and then decrease (shown for strain NBRC 3060). Interferes with activator-stimulated transcription by interaction with the RNA polymerase alpha-CTD. May function to globally reduce transcription of genes involved in growth- and development-promoting processes and to increase transcription of genes involved in thiol homeostasis, during periods of extreme stress. Catalysis of the reaction: purine nucleoside + phosphate = purine + alpha-D-ribose 1-phosphate. Cleavage of guanosine or inosine to respective bases and sugar-1-phosphate molecules. Part of a stress-induced multi-chaperone system, it is involved in the recovery of the cell from heat-induced damage, in cooperation with DnaK, DnaJ and GrpE. ATP binding |
| 6.  | A0A0E0VP69  | Nucleoside diphosphate kinase               | 16.6     | 40.94    | 6                | 1.684             | Provides the precursors necessary for DNA synthesis. Catalyzes the biosynthesis of deoxyribonucleotides from the corresponding ribonucleotides |
| 7.  | A0A0E0VNX4  | Ribosome hibernation promoting factor       | 22.2     | 16.84    | 3                | 1.679             | Provides the precursors necessary for DNA synthesis. Catalyzes the biosynthesis of deoxyribonucleotides from the corresponding ribonucleotides |
| 8.  | A0A0E0VNY8  | Regulatory protein Spx                      | 16.9     | 48.15    | 5                | 1.674             | Provides the precursors necessary for DNA synthesis. Catalyzes the biosynthesis of deoxyribonucleotides from the corresponding ribonucleotides |
| 9.  | A0A0E0VRS6  | Purine nucleoside phosphorylase DeoD-type   | 25.9     | 31.36    | 5                | 1.626             | Provides the precursors necessary for DNA synthesis. Catalyzes the biosynthesis of deoxyribonucleotides from the corresponding ribonucleotides |
| 10. | A0A0E0VMOH0 | ClpB                                        | 19.2     | 25.30    | 2                | 1.604             | Provides the precursors necessary for DNA synthesis. Catalyzes the biosynthesis of deoxyribonucleotides from the corresponding ribonucleotides |
| 11. | A0A0E0VSYO0 | 50S ribosomal protein L13                  | 16.3     | 46.21    | 11               | 0.475             | Provides the precursors necessary for DNA synthesis. Catalyzes the biosynthesis of deoxyribonucleotides from the corresponding ribonucleotides |
| 12. | A0A0E0VL11  | 30S ribosomal protein S6                   | 11.6     | 60.20    | 10               | 0.469             | Provides the precursors necessary for DNA synthesis. Catalyzes the biosynthesis of deoxyribonucleotides from the corresponding ribonucleotides |
| 13. | A0A0E0VPY0  | 30S ribosomal protein S4                   | 23.0     | 41.50    | 9                | 0.468             | Provides the precursors necessary for DNA synthesis. Catalyzes the biosynthesis of deoxyribonucleotides from the corresponding ribonucleotides |
| 14. | A0A0E0VSJ1  | Translation initiation factor IF-1          | 8.3      | 25.00    | 2                | 0.443             | Provides the precursors necessary for DNA synthesis. Catalyzes the biosynthesis of deoxyribonucleotides from the corresponding ribonucleotides |
| 15. | A0A0E0VNY5  | Ribonucleoside-diphosphate reductase beta chain | 38.8     | 14.37    | 3                | 0.424             | Provides the precursors necessary for DNA synthesis. Catalyzes the biosynthesis of deoxyribonucleotides from the corresponding ribonucleotides |

(Continued)
Based on histological evaluation as shown in Figure 5G, the skin infected with MRSA exhibited the features of increased epidermis thickness and inflammatory infiltrate in the dermis. CoQ$_0$ treatment on the infected skin significantly reduced these symptoms. OVA-induced AD exhibited hyperkeratosis, hypertrophy, and a thicker epidermis in the microscopic image. These symptoms were also visualized in the OVA/MRSA group accompanied with immune-cell
infiltration and the possibility of MRSA accumulation in the dermis. Topical CoQ₀ showed symptom amelioration of the MRSA-infected AD-like lesions. The epidermal thickness after CoQ₀ treatment was 2-fold lower than the OVA/MRSA without CoQ₀ intervention. Figure 5H reveals neutrophil infiltration in Ly6G-stained skin. This neutrophil migration could be hindered by topical CoQ₀. As with HaCaT filaggrin evaluation, CoQ₀ recovered filaggrin in the upper epidermis of the MRSA-infected skin with or without OVA intervention (Figure 5I).

We next determined the presence of the cytokines in the different groups of mice as shown in Figures 6A–E. All cytokines were elevated by MRSA invasion, indicating the induction of cutaneous inflammation. Topical CoQ₀ application significantly inhibited IL-1β and IFN-γ in the MRSA-infected mice. CoQ₀-treated infected skin showed similar levels of IL-4, IL-6, and IL-10 as vehicle control after statistical assay, although the concentration with CoQ₀ treatment was lower than that with vehicle treatment. The OVA/MRSA group generally revealed a greater increase of these cytokines than OVA or MRSA treatment alone, except the comparable IFN-γ level.

**FIGURE 5** In vitro skin absorption of CoQ₀ and in vivo topical application of CoQ₀ against MRSA-infected AD-like lesion. (A) In vitro skin deposition of CoQ₀ in Franz cell using pig, healthy mouse, and OVA-treated mouse skins. (B) In vitro skin permeation to receptor of CoQ₀ in Franz cell using pig, healthy mouse, and OVA-treated mouse skins. (C) The gross images of mouse back skin. (D) The close-up imaging by handheld digital microscopy. (E) TEWL of mice skin. (F) MRSA CFU of mice skin. (G) Skin sections represented by H&E staining. (H) Skin sections represented by Ly6G staining for observing neutrophils. (I) Skin sections represented by filaggrin staining for observing TJ distribution. Each value represents the mean ± SEM (n = 6). ***p < 0.001; *p < 0.05.
between the OVA/MRSA and MRSA groups. As shown in Figures 6B–E, CoQ₀ significantly attenuated the IL-4, IL-6, IL-10, and IFN-γ expression levels by 50%, 59%, 47%, and 62% in mouse skin with combined OVA and MRSA, respectively.

**CoQ₀ Elicits a Slight Skin Irritation**

We attempted to determine whether topical CoQ₀ induced adverse effects on mouse skin. As depicted in Figure 7A, no visible erythema or erosion occurred when the skin was applied with CoQ₀ as compared to the PBS control and vehicle only (15% ethanol/PBS). A significant elevation of TEWL was found after PBS and vehicle treatments at Day 2 because of the skin hydration by water molecules (Figure 7B). This elevation decreased after a 2-day administration. CoQ₀ application slightly increased the TEWL value as compared to vehicle control. This increase could be classified as mild. There was no difference in the skin pH and erythema quantification between the CoQ₀ and vehicle groups (Figures 7C, D). The H&E-stained histology also indicated that CoQ₀ did not irritate the skin (Figure 7E).

**DISCUSSION**

AD lesions can be infected by *S. aureus*. Management of the invasion of *S. aureus*, particularly MRSA, in AD is a major challenge in clinical conditions. Novel antibacterial and anti-inflammatory molecules are urgently needed to efficiently treat AD and the associated MRSA attack. We found that most of the benzenoid derivatives extracted from *A. cinnamomea* showed anti-MRSA activity. The anti-MRSA effect was quite different among different benzenoids. The greatest MRSA inhibition by CoQ₀ implied that the presence of the benzoquinone structure was of utmost importance for anti-MRSA activity. We calculated the physicochemical properties of the compounds by molecular modeling as shown in the Supplementary Table 1. CoQ₀ was the compound with the least lipophilicity according to Alog P. Decreasing the lipophilicity may be beneficial for potent MRSA inhibitory activity. Both compounds 5 and 6 had the structure of benzodioxole. Compound 5 with two hydroxyl moieties showed considerable anti-MRSA activity. The replacement of the hydroxyl groups with methoxyl groups (compound 6) eliminated the activity. The hydroxyl group or lower lipophilicity was required for benzodioxole to preserve the antimicrobial action. The increased hydroxyl group number and hydrophilicity were favorable for MRSA constraint as in the cases of compounds 7 and 8. The molecular size, hydrogen-bond number, and total polarity surface were not important to governing the anti-MRSA effect.

CoQ₀ is one of the predominant pigments in *A. cinnamomea*. It belongs to the family of coenzyme Q consisting of a benzoquinone structure conjugated to an isoprenoid chain from C0 to C10. CoQ₀ has the potential activity to suppress inflammation, cancer, and metabolic diseases (Wang et al., 2017). The inhibitory effect of CoQ₀ on *S. aureus* development has also been reported in previous
studies (Fan et al., 2019). CoQ₀ showed the ability to suppress the growth of both MRSA and VISA. Since the values of MIC and MBC were approximate for MRSA and VISA treated with CoQ₀, this compound can be classified as a bactericidal agent. The biofilm form of MRSA displayed differential gene expression and physiology compared to their planktonic form (Abouelhassan et al., 2018). The biofilm produced a barrier for antibiotic penetration, resulting in the further enhancement of drug resistance. CoQ₀ was active in preventing biofilm MRSA growth. In the final stage of biofilm maturation, some bacteria were dispersed from the biofilm (Chung and Toh, 2014). Our results also showed that CoQ₀ completely eradicated MRSA outside the biofilm. The amounts of proteins, RNA, and DNA of MRSA decreased after CoQ₀ treatment. The results of live/dead fluorescence microscopy, biofilm visualization, SEM, and TEM excluded MRSA membrane damage by CoQ₀. The genes related to transcription and translation, as well as the metabolic process involved in protein, RNA, and DNA synthesis, could be the anti-MRSA mechanisms of CoQ₀. DNA polymerase and topoisomerases are the important determinants of MRSA viability and the persistence of infection (Lakhundi and Zhang, 2018). Our results suggested...
that the DNA polymerase inhibition plays a role in the ability of CoQ}_{0} to impede MRSA growth.

CoQ}_{0} also restrained the activity of topoisomerase I and gyrase. Both enzymes are categorized as belonging to the family of topoisomerases helping to regulate DNA topology. Topoisomerases are potential targets for many antibacterial agents (Tse-Dinh, 2016). CoQ}_{0} may inhibit the topology of DNA during transcription, replication, and recombination. This is harmful to the survival of MRSA. The catalytic mechanism of DNA gyrase is involved in the double-strand DNA cleavage in an ATP-dependent manner (Chiriac et al., 2015). We found that some ATP-related proteins were increased by CoQ}_{0} treatment. Under the harsh stress of the CoQ}_{0} attack, the MRSA bacteria produced more energy to adapt to this adversity. The mode of action of this agent could be involved in the energy production. The proteomic assay also demonstrated a downregulation of ribosomes in CoQ}_{0}-treated pathogens. Ribosomes are the resistance proteins working against antibiotic drugs. A critical role of ribosomes is the maintenance of the substrate stability in the process of protein synthesis (Eyal et al., 2015). The inhibition of ribosomes by CoQ}_{0} may be detrimental to the protein synthesis, resulting in the total-protein lessening as observed in our results. Some topoisomerases are quite different between prokaryotes and eukaryotes. Gyrase is even absent in higher eukaryotes (Chiriac et al., 2015). DNA topoisomerases are considered as an ideal target for anti-MRSA agents because of the minimal influence on mammalian cells. The multiple targeting to different enzymes by CoQ}_{0} is advantageous to delaying the bacterial resistance because the possibility of simultaneous mutation on different targets is low.

It is worthwhile to develop the agents with combined antibacterial and anti-inflammatory actions to diminish bacteria-elicited inflammation (Gunasekaran et al., 2019). Keratinocytes are active in the immune reaction of AD by producing pro-inflammatory factors. CoQ}_{0} has been reported as an anti-inflammatory agent in the cell models of endothelial cells and macrophages (Yang et al., 2015; Yang et al., 2016). The experimental results suggested that CoQ}_{0} has an anti-inflammatory effect on stimulated keratinocytes through the inhibition of IL-6, CCL5, and CCL17. These cytokines and chemokines are all closely correlated to the pathogenesis and immune response of AD (Asahina and Maeda, 2017). CCL5 is an inflammatory chemokine produced in response to bacterial toxins (do Vale et al., 2016). CCL5 suppression is beneficial to limiting the inflammation caused by MRSA. The downregulation of TJ proteins in infected AD skin is a result of the inflammatory response (Bäslér and Brandner, 2017). TJ is involved in proliferation, differentiation, and adhesion in keratinocytes. The differentiation biomarkers filaggrin, involucrin, and integrin β1 are principal proteins in the construction of the skin-barrier property (Crawford and Dagnino, 2017). CoQ}_{0} could ameliorate the deficiency of filaggrin and integrin β1 but not involucrin in 1649b-treated HaCaT. This indicates the capability of CoQ}_{0} to protect the skin’s barrier function. This inference was verified by the TEWL and filaggrin expression in the in vivo mouse model.

A prerequisite for a topically applied agent showing therapeutic potential is effective permeation into the skin. Our data demonstrated the ability of CoQ}_{0} to penetrate into the animal skins. The small size of CoQ}_{0} (molecular weight = 182 Da) made facile permeation feasible. An optimized hydrophilic and lipophilic balance of the permeant structure is essential for achieving facile skin absorption. The higher lipophilicity causes greater delivery across the SC; however, this property may remain the permeant in the SC because of the retardation of further diffusion into viable skin (Lin et al., 2016). Yamaguchi et al. (2008) claimed the hindrance of viable skin transport for the permeant with log P > 2. CoQ}_{0} with a log P of 0.51 would be suitable to diffuse across both the SC and viable skin. We found that OVA treatment greatly increased the skin penetration of CoQ}_{0}. Impairment of TJ led to an aberrant SC barrier associated with filaggrin inhibition and TEWL extension in the case of AD-like skin.

Immunization of the mice with OVA evokes cutaneous inflammation resembling AD (Kabashima, 2013). The presence of MRSA further increased the severity of the skin inflammation and barrier-function deficiency. The downregulation of TJ in AD is a trigger of increased S. aureus invasion (Ong and Leung, 2016). The antimicrobial peptides derived by keratinocytes are finite in AD skin (Hon et al., 2013). MRSA facilely invaded the AD lesions to produce significant colonization as detected in this study. The MRSA accumulation in the skin further damaged the epidermal barrier to allow allergen transport. AD lesions are characterized by a vicious cycle of disrupted barrier and cutaneous inflammation. The intervention to repair the barrier characteristics is useful for delaying AD progression (Udkoff et al., 2017). In the present study, topical CoQ}_{0} protected the cutaneous barrier in AD-like skin. The upregulated CCL5 and CCL17 in AD not only caused the impaired integrity of the skin barrier but also induced immune-cell infiltration (Peng and Novak, 2015). Our results demonstrated that CoQ}_{0} markedly diminished chemokine upregulation in keratinocytes to ameliorate the barrier function and the severity of AD inflammation. The chemokine suppression also impeded the infiltration of neutrophils to the dermis. The antibacterial activity of CoQ}_{0} also restrained the MRSA load in AD-like skin. Our results illustrated that combined OVA and MRSA interventions significantly increased the expression of pro-inflammatory cytokines in mouse skin. Topically applied CoQ}_{0} proved to limit the cytokines in the AD-like mouse model with MRSA invasion. This inhibition may have contributed to the amelioration of AD by decreasing immune-cell infiltration.

A concern pertaining to the application of CoQ}_{0} is the safety of use. We found a cytotoxicity toward keratinocytes treated by CoQ}_{0} at higher concentrations (>7.8 μg/ml). It is reported that CoQ}_{0} is toxic to mammalian cells through direct alkylation to DNA (Takahashi et al., 2018). Although CoQ}_{0} showed some toxicity in the cell model, the in vivo skin-tolerance study manifested slight-to-mild skin irritation because the barrier function was disturbed in healthy mice. Whether CoQ}_{0} exhibits a safe therapeutic index remains to be elucidated. A future strategy to resolve the irritation could be the design and optimization of the vehicles for CoQ}_{0} to shield the possible toxicity. For AD management, combined corticosteroids and antibiotics have reportedly been successful (Fleischer, 2019). However, topical
corticosteroids induce skin thinning to compromise skin damage and increase the sensitivity to allergens and S. aureus. The use of multiple drugs usually contributes to patient noncompliance. The combined anti-MRSA and anti-inflammatory activities of CoQ0 may be useful to resolving these drawbacks.

CONCLUSIONS

The resulting compound from A. cinnamomea was tested for possible candidacy as an anti-AD agent capable of eradicating MRSA and suppressing skin inflammation. The results indicated that CoQ0 has a potential anti-MRSA effect against both the planktonic and biofilm forms. The antibacterial mechanism of CoQ0 could be the inhibition of DNA polymerase and topoisomerases. The proteomic analysis also exhibited a significant decrease of ribosomal proteins in the MRSA treated by CoQ0. A downregulation of cytokines and chemokines and the recovery of TJ-related proteins were observed in stimulated keratinocytes after CoQ0 treatment. Facile CoQ0 delivery into the skin led to the amelioration of AD-like lesions in an in vivo model. This compound also reduced the MRSA burden in the experimental AD skin. Taken together, our findings suggest the potential of topical CoQ0 as a new therapeutic option for the treatment of bacteria-infected AD.

DATA AVAILABILITY STATEMENT

The datasets for this study can be found in jPOSTrepo. The accession number is JPST000643.

REFERENCES

Abouelhassan, Y., Zhang, Y., Jin, S., and Huigens, R. WII (2018). Transcript profiling of MRSA biofilms treated with a halogenated phenazine eradicating agent: a platform for defining cellular targets and pathways critical to biofilm survival. Angew. Chem. Int. Ed. 57, 1–7. doi: 10.1002/anie.201809785

Alalaiwe, A., Wang, P., Lu, P. L., Chen, Y. P., Fang, J. Y., and Yang, S. C. (2018). Synergistic anti-MRSA activity of cationic nanostructured lipid carriers in combination with oxacillin for cutaneous application. Front. Microbiol. 9, 1493. doi: 10.3389/fmicb.2018.01493

Amin, Z. A., Ali, H. M., Alshawsh, M. A., Darvish, P. H., and Abdulla, M. A. (2015). Application of Antrodia camphorata promotes rat’s wound healing in vivo and facilitates fibroblast cell proliferation in vitro. Evid. Based Complement. Alternat. Med. 2015, 317693. doi: 10.1155/2015/317693

Asahina, R., and Maeda, S. (2017). A review of the roles of keratinocyte-derived cytokines and chemokines in the pathogenesis of atopic dermatitis in humans and dogs. Vet. Dermatol. 28, 16–e5. doi: 10.1002/vde.278368.ch2.1

Bäuserle, K., and Brandner, J. M. (2017). Tight junction in skin inflammation. Eur. J. Physiol. 469, 3–14. doi: 10.1007/s00424-016-1903-9

Buccini, M., Punch, K. A., Kaskow, B., Flematti, G. R., Skelton, B. W., Abraham, L. J., et al. (2014). Ethynylbenzenoid metabolites of Antrodia camphorata: synthesis and inhibition of TNF expression. Org. Biomol. Chem. 12, 1100. doi: 10.1039/C3OB3233F

Chen, J. J., Lin, W. J., Liao, C. H., and Shieh, P. C. (2007). Anti-inflammatory benzenoid from Antrodia camphorata. J. Nat. Prod. 70, 989–992. doi: 10.1021/np060045e

Chiang, S. S., Wang, L. T., Chen, S. Y., and Mau, J. L. (2013). Antibacterial and anti-inflammatory activities of mycelia of a medicinal mushroom from Taiwan, Taiwanofungus salmonensis (higher basidiomycetts). Int. J. Med. Mushrooms 15, 39–47. doi: 10.1615/IntJMedMushr.v15.i1.50

ETHICS STATEMENT

The animal study was reviewed and approved by Institutional Animal Care and Use Committee of Chang Gung University.

AUTHOR CONTRIBUTIONS

S-CY initiated the study and drafted the manuscript. J-YF, T-HH, and W-LC involved in the design of all experiments. W-LC, T-HH, P-WW, and Y-PC carried out the experiments. T-HL and J-YF analyzed data and wrote the manuscript. S-CY supervised the entire project. C-CC and Z-YC reviewed critically and approved the final manuscript. All authors read and approved the final manuscript.

ACKNOWLEDGMENTS

The authors are grateful for the financial support from Ministry of Science and Technology of Taiwan (MOST-107-2320-B-182-016-MY3) and Chang Gung Memorial Hospital (CMRPG2G0661-3).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2019.01445/full#supplementary-material

Chiriac, A. Z., Kloss, F., Krämer, J., Vuong, C., Hertweck, C., and Sahl, H. G. (2015). Mode of action of closthoamide: the first member of the polythioamide class of bacterial DNA gyrase inhibitors. J. Antimicrob. Chemother. 70, 2576–2588. doi: 10.1093/jac/dkv161

Chu, H. W., Chang, K. P., Hsu, C. W., Chang, I. Y. F., Liu, H. P., Chen, Y. T., et al. (2019). Identification of salivary biomarkers for oral cancer detection with untargeted and targeted quantitative proteomics approaches. Mol. Cell. Proteomics 18, 1796–1806. doi: 10.1074/mcp.RA119.001530

Chung, P. Y., and Toh, Y. S. (2014). Anti-biofilm agents: recent breakthrough against multi-drug resistant Staphylococcus aureus. Pathog. Dis. 70, 231–239. doi: 10.1111/2049-632X.12141

Crawford, M., and Dagnino, L. (2017). Scaffolding proteins in the development and maintenance of the epidermal permeability barrier. Tissue Barriers 5, e1341969. doi: 10.1080/21686370.2017.1341969

do Vale, A., Cabanes, D., and Sousa, S. (2016). Bacterial toxins as pathogen weapons against phagocytes. Front. Microbiol. 7, 42. doi: 10.3389/fmicb.2016.00042

Eyal, Z., Matzov, D., Krupkin, M., Wexelman, I., Paukner, S., Zimmerman, E., et al. (2015). Structural insights into species-specific features of the ribosome from the pathogen Staphylococcus aureus. Proc. Natl. Acad. Sci. U.S.A. 112, E3805–E3814. doi: 10.1073/pnas.151792112

Fan, Q., Yan, C., Shi, C., Xu, Y., Ma, Y., Zhang, C., et al. (2019). Inhibitory effect of coenzyme Q0 on the growth of Staphylococcus aureus. Foodborne. Pathog. Dis. 16, 317–324. doi: 10.1089/fpd.2018.2559

Feisicher, A. B. (2019). Guideline-based medicine grading on the basis of the guidelines of care for ambulatory atopic dermatitis treatment in the United States. J. Am. Acad. Dermatol. 80, 417–424. doi: 10.1016/j.jaad.2018.09.026

Franci, G., Follierio, V., Cammarota, M., Zannela, C., Sarno, F., Schiraldi, C., et al. (2018). Epigenetic modulator UVI5008 inhibits MRSA by interfering with bacterial gyrase. Sci. Rep. 8, 13117. doi: 10.1038/s41598-018-31135-9
Geethangili, M., and Tseng, Y. M. (2011). Review of pharmacological effects of Antrodia camphorata and its bioactive compounds. Evid. Based Complement. Alternat. Med. 2011, 212641. doi: 10.1093/ecast/nep108

Geethangili, M., Fang, S. H., Lai, C. H., Rao, Y. K., Lien, H. M., and Tseng, Y. M. (2010). Inhibitory effect of Antrodia camphorata constituents on the Helicobacter pylori-associated gastric inflammation. Food Chem. 119, 149–153. doi: 10.1016/j.foodchem.2009.06.006

Gunasekaran, P., Rajasekaran, G., Han, E. H., Chung, Y. H., Choi, Y. J., Yang, Y. J., et al. (2019). Cationic amphiphatic triazines with potent anti-bacterial, anti-inflammatory and anti-dermatitis properties. Sci. Rep. 9, 1292. doi: 10.1038/s41598-018-37785-z

Hon, K. L., Leung, A. K. C., and Barankin, B. (2013). Barrier repair therapy in atopic dermatitis: an overview. Am. J. Clin. Dermatol. 14, 389–399. doi: 10.1007/s40257-013-0033-9

Kabashima, K. (2013). New concept of the pathogenesis of atopic dermatitis: interplay among the barrier, allergy, and pruritus as a trinity. J. Dermatol. Sci. 70, 3–11. doi: 10.1016/j.jdermsci.2013.02.001

Kuo, Y. H., Lin, T. Y., You, Y. J., Wen, K. C., Sung, P. J., and Chiang, H. M. (2016). Antifungal and antiphotodamaging effects of ergostaren-3β-ol, isolated from Antrodia camphorata, on hairless mouse skin. Molecules 21, 1213. doi: 10.3390/molecules21091213

Lakhundi, S., and Zhang, S. (2018). Methicillin-resistant Staphylococcus aureus: molecular characterization, evolution, and epidemiology. Clin. Microbiol. Rev. 31, e00202–e00018. doi: 10.1128/CMR.00202-18

Lee, C. W., Lin, Z. C., Hu, S. C. S., Chiang, Y. C., Hsu, L. F., Lin, Y. C., et al. (2016). Urban particulate matter down-regulates filagrin via COX2 expression/PG2E2 production leading to skin barrier dysfunction. Sci. Rep. 6, 27995. doi: 10.1038/srep27995

Lien, H. M., Tseng, C. J., Huang, C. L., Lin, Y. T., Chen, C. C., and Lai, Y. Y. (2014). Antimicrobial activity of Antrodia camphorata extracts against oral bacteria. PLoS One 9, e105286. doi: 10.1371/journal.pone.0105286

Lin, C. F., Hung, C. C., Aljuffali, I. A., Huang, Y. L., Liao, W. C., and Fang, J. Y. (2016). Methylation and esterification of magnolol for ameliorating cutaneous inflammatory and anti-atopic dermatitis properties. Biochem. Pharmacol. 101, 2165–2176. doi: 10.1016/j.bopharm.2015.10.008

Lin, M. H., Li, C. C., Shu, J. C., Chu, H. W., Liu, C. C., and Wu, C. C. (2018). Anti-inflammatory and anti-angiogenic properties of coenzyme Q0 through downregulation of MMP-9/ NF-κB and upregulation of HO-1 signaling in TNF-α-activated human endothelial cells. Biochem. Pharmacol. 98, 144–156. doi: 10.1016/j.bcp.2015.09.003

Yang, H. L., Lin, M. W., Korivi, M., Wu, J. J., Liao, C. H., Chang, C. T., et al. (2016). Coenzyme Q0 regulates NF-κB/AP-1 activation and enhances Nrf2 stabilization in attenuation of LPS-induced inflammation and redox imbalance: evidence from in vitro and in vivo studies. Biochim. Biophys. Acta 1859, 246–261. doi: 10.1016/j.bbagen.2015.11.001

Yang, S. C., Huang, T. H., Chiu, C. H., Chou, W. L., Alalaiwe, A., Yeh, Y. C., et al. (2018). The atopic dermatitis-like lesion and the associated MRSA infection and barrier dysfunction can be alleviated by 2,4-dimethoxy-6-methylbenzene-1,3-diol from Antrodia camphorata. J. Dermatol. Sci. 92, 188–196. doi: 10.1016/j.jdermsci.2018.09.002

Yang, S. C., Tang, K. W., Lin, C. H., Alalaiwe, A., Tseng, C. H., and Fang, J. Y. (2019). Discovery of furoanquinone derivatives as a novel class of DNA polymerase and gyrase inhibitors for MRSA eradication in cutaneous infection. Front. Microbiol. 10, 1197. doi: 10.3389/fmicb.2019.01197

Yen, I. C., Shi, L. S., Chung, M. C., Ahmetaj-Shala, B., Chang, T. C., and Lee, S. Y. (2018). Antrolone, a novel benzoid derived from Antrodia cinnamomea, inhibits the LPS-induced inflammatory response in RAW264.7 macrophage cells by balancing the NF-κB and Nrf2 pathways. Am. J. Chin. Med. 46, 1297–1313. doi: 10.1142/S0129053918500684

Yu, P. W., Chang, Y. C., Liou, R. F., Lee, T. H., and Tzean, S. S. (2016). pks63787, a benzoquinone antibiotic that displays anti-angiogenic and anti-inflammatory activities. Future Med. Chem. 8, 1485–1491. doi: 10.1016/j.fncap.2015.08.007

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Chou, Lee, Huang, Wang, Chen, Chang, Fang and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction which does not comply with these terms.